This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Academic Highlights

Managing ADHD in Children, Adolescents, and Adults With Comorbid Anxiety.

Lenard A. Adler, MD; Russell A. Barkley, PhD; Jeffrey H. Newcorn, MD; Thomas J. Spencer, MD; and Margaret D. Weiss, MD, PhD;

Published: March 15, 2007

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Attention-deficit/hyperactivity disorder (ADHD) is a relatively common disorder, estimated to affect 3% to 6% of children1 and 4.5% of adults.2 Individuals with ADHD, their families, and society as a whole bear the burden of this disorder, even though effective pharmacologic and psychosocial treatments are available. Annual direct medical costs for children with ADHD have been found to be approximately 50% to 75% more than those of children without ADHD,3,4 and family members of patients with ADHD have direct and indirect costs that are almost double those of family members of children without ADHD.4


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 68

Quick Links: ADHD , Neurodevelopmental

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Clinical and Practical Psychopharmacology

Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia

Dr Andrade discusses whether or not recent findings support the use of NAC as antipsychotic augmentation in...

Read More...